Search results for "Progression"

showing 10 items of 1251 documents

THE USE OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (ANAKINRA) IN KAWASAKI DISEASE: A RETROSPECTIVE CASES SERIES

2018

Introduction: Persistent fever and inflammation after infusion of 2g/kg of IVIG, the standard treatment of KD represents a high-risk situation for coronary aneurysms in Kawasaki disease. Identifying patients at risk for IVIG resistance is difficult outside the Asian population, and there remains a critical unmet need to identify an anti-inflammatory treatment that is efficacious in all KD patients. Recent evidence from studies in animals and humans suggest a critical role for interleukin-1 (IL-1) α and β in the pathogenesis of KD. Objectives: To identify the clinical characteristics, reasons for use and response to treatment with anakinra in a retrospective series of patients with Kawasaki …

Male0301 basic medicineBLOCKADEPlacebo-controlled studyCHILDRENSUSCEPTIBILITYPLACEBO-CONTROLLED TRIALPediatricsDOUBLE-BLIND0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaRetrospective StudieINTERLEUKIN 1 RECEPTOR ANTAGONIST ANAKINRA KAWASAKI DISEASEImmunology and AllergyJUVENILE IDIOPATHIC ARTHRITISChildPediatricAnakinra coronary artery aneurysmPrognosis1107 ImmunologyChild PreschoolDisease ProgressionFemaleVasculitisLife Sciences & BiomedicineHumanmedicine.drugVasculitismusculoskeletal diseasesAutoinflammatory diseaseVasculitimedicine.medical_specialtyMyocarditisPrognosiImmunologyMucocutaneous Lymph Node SyndromeAnakinra coronary artery aneurysms03 medical and health sciencesInternal medicineINFLIXIMABMANAGEMENTmedicineINTRAVENOUS IMMUNOGLOBULINHumansRetrospective Studies030203 arthritis & rheumatologyAnakinraScience & TechnologyKawasaki diseasebusiness.industryInfantReceptors Interleukin-1Retrospective cohort studymedicine.diseaseInfliximabInterleukin 1 Receptor Antagonist Protein030104 developmental biologyInterleukin 1 receptor antagonistKawasaki diseasebusinessInterleukin-1
researchProduct

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab pl…

2019

10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC. This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.…

Male0301 basic medicineCancer ResearchEsophageal NeoplasmsReceptor ErbB-2SURGERYmedicine.medical_treatmentGastroenterologyStudy ProtocolNEOADJUVANT CHEMOTHERAPYAntineoplastic Agents Immunological0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesOXALIPLATINNetherlandsAged 80 and overDOCETAXELMiddle AgedOPEN-LABELlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenNeoadjuvant TherapyProgression-Free SurvivalTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleGastro-esophageal junction cancerEsophagogastric JunctionFluorouracilPertuzumabmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsCAPECITABINEAdenocarcinomaAntibodies Monoclonal Humanizedlcsh:RC254-282CapecitabineYoung Adult03 medical and health sciencesBreast cancerStomach NeoplasmsInternal medicineHER2Republic of KoreaREGRESSIONGeneticsmedicineHumansBREAST-CANCERPerioperative PeriodAgedCisplatinChemotherapyPerioperative chemotherapyPertuzumabbusiness.industryTrastuzumabmedicine.diseaseOxaliplatin030104 developmental biologyCisplatinbusinessGastric cancerFollow-Up Studies
researchProduct

Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population‐Based Gutenberg Health Study

2018

Background Preclinical data have indicated a link between use of vitamin K antagonists ( VKA ) and detrimental effects on vascular structure and function. The objective of the present study was to determine the relationship between VKA intake and different phenotypes of subclinical cardiovascular disease in the population. Methods and Results Clinical and laboratory data, as well as medical–technical examinations were assessed from 15 010 individuals aged 35 to 74 years during a highly standardized 5‐hour visit at the study center of the population‐based Gutenberg Health Study. In total, the study sample comprised 287 VKA users and 14 564 VKA nonusers. Multivariable analysis revealed an in…

Male0301 basic medicineEpidemiologyPROGRESSION030204 cardiovascular system & hematologyVitamin kCarotid Intima-Media ThicknessTHERAPYGastroenterologyAdrenomedullin0302 clinical medicineRisk Factorscardiovascular diseaseGermanyAtrial FibrillationNatriuretic Peptide BrainMatrix gla proteinOriginal ResearchVenous Thrombosisoral anticoagulationRISKbiologyMiddle AgedStrokevitamin K antagonistsC-Reactive ProteinCardiovascular DiseasesFemaleCardiology and Cardiovascular MedicineAtrial Natriuretic Factormedicine.drugAdultmedicine.medical_specialtyPopulation basedMATRIX GLA-PROTEINWARFARIN03 medical and health sciencesVascular StiffnessInternal medicineORAL ANTICOAGULANTmedicineHumansAnkle Brachial IndexVascular structureProtein PrecursorsAgedInflammationVascular diseasebusiness.industryWarfarinAnticoagulantsFibrinogenStroke Volumepharmacogenomic variantsARTERIALmedicine.diseasePreclinical dataPeptide FragmentsCALCIFICATION030104 developmental biologyAsymptomatic DiseasesPhenprocoumonbiology.proteinPulmonary EmbolismbusinessCalcificationJournal of the American Heart Association
researchProduct

Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception

2016

Adult neural stem cells reside in a specialized niche in the subventricular zone (SVZ). Throughout life they give rise to adult-born neurons in the olfactory bulb (OB), thus contributing to neural plasticity and pattern discrimination. Here, we show that the neurovascular protein EGFL7 is secreted by endothelial cells and neural stem cells (NSCs) of the SVZ to shape the vascular stem-cell niche. Loss of EGFL7 causes an accumulation of activated NSCs, which display enhanced activity and re-entry into the cell cycle. EGFL7 pushes activated NSCs towards quiescence and neuronal progeny towards differentiation. This is achieved by promoting Dll4-induced Notch signalling at the blood vessel-stem …

Male0301 basic medicineGeneral Physics and AstronomyNEURAL STEM-CELLSMOUSEMiceSUBEPENDYMAL ZONENeural Stem CellsLateral VentriclesLINEAGE PROGRESSIONBRAININ-VIVOMice KnockoutNeuronal PlasticityMultidisciplinaryCell CycleQNeurogenesisNICHEAnatomyNeural stem cellCell biologyAdult Stem Cellsmedicine.anatomical_structureSignal TransductionSTIMULATES NEUROGENESISEGF Family of ProteinsNeurogenesisScienceNotch signaling pathwaySubventricular zoneBiologyInhibitory postsynaptic potentialArticleGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesNeuroplasticitymedicineBiological neural networkAnimalsCalcium-Binding ProteinsProteinsGeneral ChemistryOlfactory PerceptionENDOTHELIAL-CELLSnervous system diseasesOlfactory bulbMice Inbred C57BLSELF-RENEWAL030104 developmental biologynervous system
researchProduct

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis

2015

We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 off or 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7–10.9) and 5 months (95% CI 3.6–6.7) respectively (P = 0.012). No difference wa…

Male0301 basic medicineIndolesTime FactorsGIST; exon 11; imatinib; second line; sunitinibGastroenterologyExon 11Exon0302 clinical medicineSecond linehemic and lymphatic diseasesSunitinibMedicineAged 80 and overGiSTSunitinibExonsMiddle AgedProto-Oncogene Proteins c-kitOncology030220 oncology & carcinogenesisDisease ProgressionImatinib MesylateFemaleResearch PaperGISTmedicine.drugAdultmedicine.medical_specialtyGastrointestinal Stromal TumorsAntineoplastic AgentsDisease-Free Survival03 medical and health sciencesInternal medicineHumansPyrrolesAgedRetrospective StudiesSecond lineSecond line treatmentDose-Response Relationship Drugbusiness.industryRetrospective cohort studyImatinibSurgery030104 developmental biologyImatinib mesylateMutationImatinibbusinessOncotarget
researchProduct

CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis

2017

Elevated cerebrospinal fluid (CSF), Neurofilament Light (NF-L) and phosphorylated Heavy (pNF-H) chain levels have been found in Amyotrophic Lateral Sclerosis (ALS), with studies reporting a correlation of both neurofilaments (NFs) with the disease progression. Here, we measured NF-L and pNF-H concentrations in the CSF of ALS patients from a single tertiary Center and investigated their relationship with disease-related variables. A total of 190 ALS patients (Bulbar, 29.9%; Spinal, 70.1%; M/F = 1.53) and 130 controls with mixed neurological diseases were recruited. Demographic and clinical variables were recorded, and Delta FS was used to rate the disease progression. Controls were divided i…

Male0301 basic medicineNeurologypNF-HNeurofilamentKaplan-Meier EstimateGastroenterology0302 clinical medicineCerebrospinal fluidNeurofilament ProteinsMedicinePhosphorylationAmyotrophic lateral sclerosisNeuroradiologyNeurofilament ProteinMiddle AgedPrognosisNeurologyArea Under CurveCohortDisease ProgressionFemaleHumanmedicine.medical_specialtyPrognostic variableNeurofilamentPrognosiCSFEnzyme-Linked Immunosorbent AssayFollow-Up StudieDiagnosis Differential03 medical and health sciencesOligoclonal BandInternal medicineHumansAgedInflammationbusiness.industryAmyotrophic Lateral SclerosisOligoclonal BandsBiomarkermedicine.disease030104 developmental biologyROC CurveNF-LNeurology (clinical)ALSDifferential diagnosisbusinessBiomarkers030217 neurology & neurosurgeryAmyotrophic Lateral SclerosiFollow-Up StudiesJournal of Neurology
researchProduct

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract can…

2019

Background To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeutic approaches including targeted agents and tyrosine kinase inhibitors (TKI) have demonstrated disappointing results, highlighting the complexity of CCA. Recently, drugs aiming at the inhibition of HER-receptors have shown first therapeutic benefit in patients with late stage disease. The aim of this phase I study was to test the dose level toxicities (DLTs), safety and efficacy of afatinib, a highly specific panErbB family receptor TKI, in chemotherapy naive patients with ad…

Male0301 basic medicineOncologyCancer ResearchAfatinibDeoxycytidineTranslational Research BiomedicalCholangiocarcinoma0302 clinical medicineSurgical oncologyAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasismedia_commonAged 80 and overpanHER inhibitionMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmunohistochemistryErbB ReceptorsBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisBiomarker (medicine)FemaleTyrosine kinaseSignal TransductionResearch Articlemedicine.drugAdultDrugmedicine.medical_specialtyBIBW 2992media_common.quotation_subjectEGFRAfatiniblcsh:RC254-28203 medical and health sciencesInternal medicineGeneticsmedicineHumansProgression-free survivalAgedNeoplasm StagingCisplatinbusiness.industryGemcitabineGemcitabine030104 developmental biologyCisplatinbusinessBiomarkersBMC Cancer
researchProduct

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy aft…

2016

Tumor immunologic microenvironment is strongly involved in tumor progression and the presence of tumor infiltrating lymphocytes (TIL) with different phenotypes has been demonstrated to be of prognostic relevance in different malignancies. We investigated whether TIL infiltration of tumor tissues could also predict the outcome of prostate cancer patients. To this end, we carried out a retrospective analysis correlating the outcome of locally advanced prostate cancer patients undergone salvage radiotherapy upon relapse after radical surgery with the infiltration by different TIL populations. Twenty-two patients with resectable prostate cancer, with a mean age of 67 (+/−3.93) years, who receiv…

Male0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorChemokyne Receptor 7Prostate cancer0302 clinical medicineRecurrencePD-1Tumor MicroenvironmentForkhead Transcription Factorshemic and immune systemsprostate cancerPrimary tumorChemokyne Receptor 7; disease-free survival; FoxP3; overall survival; PD-1; prognosis; prostate cancer; radiotherapy; T regulators lymphocytes; tumor infiltrating lymphocytesOncologytumor infiltrating lymphocytes030220 oncology & carcinogenesisMolecular MedicineprognosiResearch PaperReceptors CCR7medicine.medical_specialtydisease-free survivaloverall survivalchemical and pharmacologic phenomena03 medical and health sciencesLymphocytes Tumor-InfiltratingMedian follow-upFoxP3Internal medicineChemokyne Receptor 7; disease-free survival; FoxP3; overall survival; PD-1; prognosis; prostate cancer; radiotherapy; T regulators lymphocytes; tumor infiltrating lymphocytes; Molecular Medicine; Oncology; Pharmacology; Cancer ResearchT regulators lymphocytesmedicineHumansProgression-free survivalRadical surgeryradiotherapyAgedSalvage TherapyPharmacologybusiness.industryTumor-infiltrating lymphocytesProstatic Neoplasmsmedicine.diseaseRadiation therapyT regulators lymphocyte030104 developmental biologyTumor progressionprognosistumor infiltrating lymphocytebusinessCancer Biology & Therapy
researchProduct

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis

2018

ObjectivePrimary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications.DesignWe collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportiona…

Male0301 basic medicineOncologyCandidate geneCholangitismedicine.medical_treatmentMedizinTrasplantament hepàticGenome-wide association studyKaplan-Meier EstimateLIVER FIBROSISLiver transplantationBioinformaticsSclerosingOral and gastrointestinalPrimary sclerosing cholangitis; genetics; liver transplantationCohort StudiesACTIVATION0302 clinical medicineMED/12 - GASTROENTEROLOGIAMULTIPLE2.1 Biological and endogenous factorsEPIDEMIOLOGYgeneticsAetiologyCIRRHOSISliver transplantationBilious diseases and biliousnessPrimary sclerosing cholangitisLiver Diseasedigestive oral and skin physiologyGastroenterologySingle NucleotidePrimary sclerosing cholangitiMiddle Aged3. Good healthULCERATIVE-COLITISDisease ProgressionFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyCholangitis SclerosingChronic Liver Disease and CirrhosisClinical SciencesMalalties del tracte biliarSingle-nucleotide polymorphismHEPATIC STELLATE CELLSPolymorphism Single NucleotideInternational PSC Study GroupArticlePrimary sclerosing cholangitisPaediatrics and Reproductive Medicine03 medical and health sciencesRare DiseasesClinical ResearchInternal medicineGeneticsmedicineHumansPolymorphismGENOME-WIDE ASSOCIATIONAlleleDigestive Diseases - (Gallbladder)Survival analysisProportional Hazards ModelsMALIGNANCYThe UK PSC ConsortiumTransplantationGastroenterology & Hepatologybusiness.industryProportional hazards modelmedicine.diseaseRISK LOCILogistic Models030104 developmental biology3121 General medicine internal medicine and other clinical medicinegeneticHepatic transplantationThrombospondinsDigestive DiseasesbusinessGenèticaGut
researchProduct

Genetic systems for a new approach to risk of progression of diabetic retinopathy.

2016

OBJECTIVE: To evaluate the risk of progression of diabetic retinopathy (DR) using new strategies to obtain genetic information in type 2 diabetes (T2D) based on interfering ribonucleic acid (RNA). MATERIAL AND METHODS: A prospective multicentre case-control study of 132 participants was distributed into: T2D with (+DR) or without (-DR) (T2DG; n=77), and a control group (CG; n=55). After an eye examination and personal interview, tears were collected for molecular analysis (expression of microRNAs [miRNAs] (miRCURY ARN Isolation Kit, Qiagen)]. Libraries, 137 vs. 140bp (GeneMapper, Applied Biosystems), were obtained in 18 samples (T2DG+DR=6; T2DG-DR=6; CG=6) by performing next-generation sequ…

Male0301 basic medicineOncologyMicro RNAsmedicine.medical_specialtyBiomarcadores preclinicosType 2 diabetesMicro-ARNBioinformaticsRisk AssessmentInterference by RNA03 medical and health sciencesDiabetic retinopathyInternal medicineType 2 diabetes mellitusmedicineHumansProspective StudiesFamily historyAgedDiabetic Retinopathymedicine.diagnostic_testSequence Analysis RNAbusiness.industryPre-clinical biomarkersType 2 Diabetes MellitusGenetic systemsRetinopatia diabeticaGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseInterferencia por ARNMolecular analysisDiabetes mellitus tipo 2030104 developmental biologyDiabetes Mellitus Type 2Eye examinationCase-Control StudiesDisease ProgressionTearsFemalebusinessBiomarcadores preclínicos Diabetes mellitus tipo 2 Diabetic retinopathy Interference by RNA Interferencia por ARN Micro RNAs Micro-ARN Pre-clinical biomarkers Retinopatía diabética Type 2 diabetes mellitus
researchProduct